vs
Harmony Biosciences Holdings, Inc.（HRMY）とBRC Group Holdings, Inc.（RILY）の財務データ比較。上の社名をクリックして会社を切り替えられます
Harmony Biosciences Holdings, Inc.の直近四半期売上が大きい（$243.8M vs $188.3M、BRC Group Holdings, Inc.の約1.3倍）。BRC Group Holdings, Inc.の純利益率が高く（47.9% vs 9.2%、差は38.7%）。Harmony Biosciences Holdings, Inc.の前年同期比売上増加率が高い（21.1% vs -21.9%）。過去8四半期でHarmony Biosciences Holdings, Inc.の売上複合成長率が高い（25.6% vs -15.4%）
ハーモニーバイオサイエンシズホールディングスは商業段階のバイオ医薬品企業で、希少神経疾患や中枢神経疾患向け革新的治療法の開発・事業化に注力しています。主な市場は米国で、ナルコレプシーをはじめとする睡眠関連中枢神経疾患の患者向け製品を提供しています。
HRMY vs RILY — 直接比較
売上が大きい
HRMY
1.3倍大きい
$188.3M
売上成長率が高い
HRMY
+43.0%の差
-21.9%
純利益率が高い
RILY
純利益率が38.7%高い
9.2%
2年売上CAGRが高い
HRMY
2年複合成長率
-15.4%
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $243.8M | $188.3M |
| 純利益 | $22.5M | $90.3M |
| 粗利率 | 71.9% | 79.5% |
| 営業利益率 | 15.8% | 32.3% |
| 純利益率 | 9.2% | 47.9% |
| 売上前年比 | 21.1% | -21.9% |
| 純利益前年比 | -54.6% | 1710.8% |
| EPS（希薄化後） | $0.38 | $2.78 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上HRMYRILY
| Q4 25 | $243.8M | $188.3M | ||
| Q3 25 | $239.5M | $215.3M | ||
| Q2 25 | $200.5M | $188.2M | ||
| Q1 25 | $184.7M | $197.2M | ||
| Q4 24 | $201.3M | $241.0M | ||
| Q3 24 | $186.0M | $225.5M | ||
| Q2 24 | $172.8M | $256.0M | ||
| Q1 24 | $154.6M | $263.4M |
純利益HRMYRILY
| Q4 25 | $22.5M | $90.3M | ||
| Q3 25 | $50.9M | $91.1M | ||
| Q2 25 | $39.8M | $139.5M | ||
| Q1 25 | $45.6M | $-10.0M | ||
| Q4 24 | $49.5M | $-5.6M | ||
| Q3 24 | $46.1M | $-284.4M | ||
| Q2 24 | $11.6M | $-433.6M | ||
| Q1 24 | $38.3M | $-49.2M |
粗利率HRMYRILY
| Q4 25 | 71.9% | 79.5% | ||
| Q3 25 | 75.1% | 83.7% | ||
| Q2 25 | 81.0% | 81.3% | ||
| Q1 25 | 82.7% | 81.4% | ||
| Q4 24 | 73.0% | 79.8% | ||
| Q3 24 | 77.0% | 82.1% | ||
| Q2 24 | 81.4% | 84.5% | ||
| Q1 24 | 82.2% | 85.3% |
営業利益率HRMYRILY
| Q4 25 | 15.8% | 32.3% | ||
| Q3 25 | 27.3% | 30.4% | ||
| Q2 25 | 24.0% | 5.7% | ||
| Q1 25 | 30.4% | -31.2% | ||
| Q4 24 | 27.7% | -69.2% | ||
| Q3 24 | 33.2% | -36.4% | ||
| Q2 24 | 12.4% | -90.8% | ||
| Q1 24 | 33.7% | -6.1% |
純利益率HRMYRILY
| Q4 25 | 9.2% | 47.9% | ||
| Q3 25 | 21.2% | 42.3% | ||
| Q2 25 | 19.8% | 74.1% | ||
| Q1 25 | 24.7% | -5.1% | ||
| Q4 24 | 24.6% | -2.3% | ||
| Q3 24 | 24.8% | -126.1% | ||
| Q2 24 | 6.7% | -169.4% | ||
| Q1 24 | 24.8% | -18.7% |
EPS（希薄化後）HRMYRILY
| Q4 25 | $0.38 | $2.78 | ||
| Q3 25 | $0.87 | $2.91 | ||
| Q2 25 | $0.68 | $4.50 | ||
| Q1 25 | $0.78 | $-0.39 | ||
| Q4 24 | $0.85 | $-0.01 | ||
| Q3 24 | $0.79 | $-9.39 | ||
| Q2 24 | $0.20 | $-14.35 | ||
| Q1 24 | $0.67 | $-1.71 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $775.3M | $226.6M |
| 総負債低いほど良い | $163.7M | $1.4B |
| 株主資本純資産 | $870.2M | $-171.5M |
| 総資産 | $1.3B | $1.7B |
| 負債/資本比率低いほどレバレッジが低い | 0.19× | — |
8四半期トレンド — 暦四半期で整列
現金・短期投資HRMYRILY
| Q4 25 | $775.3M | $226.6M | ||
| Q3 25 | $672.6M | $184.2M | ||
| Q2 25 | $565.3M | $267.4M | ||
| Q1 25 | $507.0M | $138.3M | ||
| Q4 24 | $467.2M | $146.9M | ||
| Q3 24 | $410.5M | $159.2M | ||
| Q2 24 | $346.9M | $236.9M | ||
| Q1 24 | $372.4M | $190.7M |
総負債HRMYRILY
| Q4 25 | $163.7M | $1.4B | ||
| Q3 25 | $168.5M | $1.3B | ||
| Q2 25 | $172.1M | $1.3B | ||
| Q1 25 | $175.7M | $1.4B | ||
| Q4 24 | $179.3M | $1.5B | ||
| Q3 24 | $182.8M | — | ||
| Q2 24 | $186.4M | — | ||
| Q1 24 | $190.0M | — |
株主資本HRMYRILY
| Q4 25 | $870.2M | $-171.5M | ||
| Q3 25 | $835.1M | $-260.5M | ||
| Q2 25 | $773.1M | $-351.7M | ||
| Q1 25 | $720.5M | $-496.8M | ||
| Q4 24 | $659.2M | $-488.2M | ||
| Q3 24 | $596.8M | $-497.6M | ||
| Q2 24 | $538.6M | $-218.3M | ||
| Q1 24 | $515.4M | $228.4M |
総資産HRMYRILY
| Q4 25 | $1.3B | $1.7B | ||
| Q3 25 | $1.2B | $1.7B | ||
| Q2 25 | $1.1B | $1.5B | ||
| Q1 25 | $1.1B | $1.5B | ||
| Q4 24 | $999.2M | $1.8B | ||
| Q3 24 | $928.1M | $2.2B | ||
| Q2 24 | $858.4M | $3.2B | ||
| Q1 24 | $847.0M | $5.0B |
負債/資本比率HRMYRILY
| Q4 25 | 0.19× | — | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.22× | — | ||
| Q1 25 | 0.24× | — | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | 0.31× | — | ||
| Q2 24 | 0.35× | — | ||
| Q1 24 | 0.37× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $126.2M | $26.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $126.0M | — |
| FCFマージンFCF / 売上 | 51.7% | — |
| 設備投資強度設備投資 / 売上 | 0.0% | — |
| キャッシュ転換率営業CF / 純利益 | 5.61× | 0.29× |
| 直近12ヶ月FCF直近4四半期 | $347.9M | — |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローHRMYRILY
| Q4 25 | $126.2M | $26.2M | ||
| Q3 25 | $108.7M | $-60.6M | ||
| Q2 25 | $79.3M | $-25.6M | ||
| Q1 25 | $34.0M | $184.0K | ||
| Q4 24 | $75.6M | $-2.7M | ||
| Q3 24 | $70.5M | $19.5M | ||
| Q2 24 | $42.6M | $111.5M | ||
| Q1 24 | $31.1M | $135.4M |
フリーキャッシュフローHRMYRILY
| Q4 25 | $126.0M | — | ||
| Q3 25 | $108.7M | — | ||
| Q2 25 | $79.3M | — | ||
| Q1 25 | $33.9M | — | ||
| Q4 24 | $75.0M | — | ||
| Q3 24 | $70.5M | — | ||
| Q2 24 | $42.0M | — | ||
| Q1 24 | $31.1M | — |
FCFマージンHRMYRILY
| Q4 25 | 51.7% | — | ||
| Q3 25 | 45.4% | — | ||
| Q2 25 | 39.6% | — | ||
| Q1 25 | 18.3% | — | ||
| Q4 24 | 37.3% | — | ||
| Q3 24 | 37.9% | — | ||
| Q2 24 | 24.3% | — | ||
| Q1 24 | 20.1% | — |
設備投資強度HRMYRILY
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.0% | — |
キャッシュ転換率HRMYRILY
| Q4 25 | 5.61× | 0.29× | ||
| Q3 25 | 2.14× | -0.66× | ||
| Q2 25 | 1.99× | -0.18× | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | 1.53× | — | ||
| Q3 24 | 1.53× | — | ||
| Q2 24 | 3.68× | — | ||
| Q1 24 | 0.81× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
HRMY
セグメントデータなし
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
